When should Corynebacterium striatum be treated and what is the recommended antimicrobial therapy?

Treatment of Corynebacterium striatum

Corynebacterium striatum should be treated when isolated from normally sterile sites (blood, body fluids, tissues) or when causing device-associated infections, as it is increasingly recognized as a true pathogen rather than a contaminant, particularly in healthcare settings. 1, 2

When to Treat

• Treat C. striatum when isolated from blood cultures, especially in the setting of catheter-related bloodstream infections (CRBSI), as it demonstrates pathogenicity in 87% of hardware- or device-associated cases. 3

• Treat when isolated from normally sterile body fluids or tissues, including postoperative intra-abdominal infections, skin and soft tissue infections, osteoarticular infections, and chronic contiguous osteomyelitis. 2, 4

• Do not dismiss C. striatum as a contaminant in polymicrobial infections—targeted therapy against this pathogen is typically required for cure, particularly when surgical intervention is involved. 2

• Consider treatment in long-term hospitalized patients with indwelling devices, as nosocomial transmission occurs and the organism shows enhanced virulence in this population. 4, 5

First-Line Antimicrobial Therapy

• Vancomycin is the antibiotic of choice for C. striatum infections, with 100% susceptibility demonstrated across multiple isolates in systematic reviews. 1

• For severe invasive infections, vancomycin can be used in monotherapy or in combination with piperacillin-tazobactam, which also shows 100% susceptibility. 1

• The median duration of antimicrobial therapy is 25 days, with most patients (84.3%) showing clinical improvement by day 14. 4

Alternative Agents

• Linezolid, teicoplanin, or daptomycin may be used for severe infections as alternatives to vancomycin. 1

• Oral minocycline is often administered in patients requiring long-term treatment, as most strains remain susceptible to tetracyclines (92.5% susceptibility). 4

• Amoxicillin-clavulanate and cefuroxime show 100% susceptibility and may be used for mild infections. 1

• For patients requiring prolonged therapy who are clinically stable, an early switch to oral linezolid after initial intravenous vancomycin has been successfully employed in endocarditis cases. 6

Critical Resistance Patterns

• C. striatum commonly exhibits multidrug resistance: 71% of isolates are resistant to all oral antimicrobial drugs tested, including penicillin, tetracycline, clindamycin, erythromycin, and ciprofloxacin. 3

• High-level resistance is documented to fluoroquinolones, most β-lactams (except amoxicillin-clavulanate and piperacillin-tazobactam), aminoglycosides, macrolides, lincosamides, and cotrimoxazole. 1

• Emergence of daptomycin nonsusceptibility during treatment occurs in 36% of patients with bacteremia, leading to clinical failure in 45% of cases, despite initial susceptibility. 7

• Non-susceptibility to tetracyclines (7.5%) is associated with tet(W) carriage, limiting minocycline as a universal option. 4

Device Management

• For catheter-related infections, remove the catheter when feasible—this is essential for source control and markedly improves outcomes. 8, 2

• Patients with hardware-associated C. striatum infections require significantly longer parenteral antimicrobial therapy compared to coagulase-negative staphylococcal infections (mean 69 days vs. 25 days). 3

• Surgical debridement is frequently required (44.4% of cases in endocarditis series) and is typically necessary for cure in chronic contiguous osteomyelitis. 2, 6

Treatment Duration

• For uncomplicated CRBSI with catheter removal, treat for 10-14 days. 8

• For hardware-associated infections without device removal, prolonged therapy of 4-6 weeks or longer is typically required. 8, 3

• For endocarditis or persistent bacteremia >72 hours, extend therapy to 4-6 weeks. 8, 6

Common Pitfalls

• Do not assume C. striatum is a contaminant—the crude mortality rate is 15.7% at 90 days post-diagnosis, and fatal outcomes occur in nearly 20% of invasive infections despite treatment. 1, 4

• Do not rely on oral antimicrobials for initial therapy in serious infections, as most strains are resistant to all orally bioavailable agents. 3

• Monitor for daptomycin treatment failure if used—clinical failure and emergence of resistance during therapy are common. 7

• Recognize that nosocomial transmission occurs—implement infection control measures when multiple cases are identified in the same unit. 4, 5